Supernus Q1 revenue flat at $153.8M; Qelbree sales triple to $25.8M; raises FY 2023 guidance

SUPERNUS PHARMACEUTICALS, INC.

2023-Q1 EPS reported $0.29 revenue$153,764,000

Q1 total revenues $153.8M (+1% YoY); GAAP operating earnings $5.2M vs $2.0M; net earnings $16.9M ($0.29/sh) vs $25.6M ($0.43/sh).
Qelbree net sales $25.8M (vs $8.3M YoY); GOCOVRI $26.0M (+15%); Trokendi XR fell 45% to $34.8M due to generic entry.
Excluding Trokendi XR, net product sales up 25% YoY; total IQVIA Qelbree prescriptions rose 14% QoQ to 134,530.
Raising FY 2023 GAAP operating loss guidance to $(30)-$(10)M from $(40)-$(10)M; non-GAAP operating earnings raised to $75-100M.
Repaid $402.5M of 0.625% convertible notes due 2023 on April 1; credit line balance of $78.4M to be fully repaid by Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SUPERNUS PHARMACEUTICALS, INC. reported First Quarter 2023 results: revenue 153.8 million, net income 16.9 million, EPS 0.29. Guidance raised.

Period: First Quarter 2023
Revenue: 153.8 million
Net income: 16.9 million
EPS: 0.29
Guidance: raised
Result: reported results

Exact text from the filing

Supernus Announces First Quarter 2023 Financial Results • First quarter 2023 total revenues of $153.8 million, compared to $152.5 million in first quarter 2022 – Qelbree ® net product sales of $25.8 million, compared to $8.3 million in first quarter 2022 – GOCOVRI ® net product sales of $26.0 million, compared to $22.6 million in first quarter 2022 – Excluding net product sales of Trokendi XR ® in both periods, total net product sales increased 25% • First quarter 2023 GAAP operating earnings of $5.2 million, compared to $2.0 million in first quarter 2022 • First quarter 2023 non-GAAP operating earnings of $30.5 million, compared to $28.0 million in first quarter 2022 • Raises full year 2023 GAAP and non-GAAP operating earnings guidance ROCKVILLE, MD, May 9, 2023 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for

View on SEC.gov

Browse all earnings releases →

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-23-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.